[go: up one dir, main page]

MX2015004649A - Metodos de modificacion de celulas huesped. - Google Patents

Metodos de modificacion de celulas huesped.

Info

Publication number
MX2015004649A
MX2015004649A MX2015004649A MX2015004649A MX2015004649A MX 2015004649 A MX2015004649 A MX 2015004649A MX 2015004649 A MX2015004649 A MX 2015004649A MX 2015004649 A MX2015004649 A MX 2015004649A MX 2015004649 A MX2015004649 A MX 2015004649A
Authority
MX
Mexico
Prior art keywords
methods
host cell
cell modification
host cells
nucleic acid
Prior art date
Application number
MX2015004649A
Other languages
English (en)
Other versions
MX365435B (es
Inventor
Michael Wacker
Michael Kowarik
Fabiana Fernandez
Original Assignee
Glycovaxyn Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycovaxyn Ag filed Critical Glycovaxyn Ag
Publication of MX2015004649A publication Critical patent/MX2015004649A/es
Publication of MX365435B publication Critical patent/MX365435B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185Escherichia
    • C12R2001/19Escherichia coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52Genes encoding for enzymes or proenzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70Vectors or expression systems specially adapted for E. coli
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1051Hexosyltransferases (2.4.1)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/30Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/40Systems of functionally co-operating vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos novedosos de inserción de secuencias de ácido nucleico en células huésped. En la presente también se describen células huésped genéticamente estables que comprenden secuencias de ácido nucleico insertadas, y métodos para utilizar tales células huésped en la generación de proteínas.
MX2015004649A 2012-10-12 2013-10-11 Metodos de modificacion de celulas huesped. MX365435B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713281P 2012-10-12 2012-10-12
PCT/EP2013/071328 WO2014057109A1 (en) 2012-10-12 2013-10-11 Methods of host cell modification

Publications (2)

Publication Number Publication Date
MX2015004649A true MX2015004649A (es) 2016-01-12
MX365435B MX365435B (es) 2019-06-03

Family

ID=49326691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015004649A MX365435B (es) 2012-10-12 2013-10-11 Metodos de modificacion de celulas huesped.

Country Status (16)

Country Link
US (2) US20150267207A1 (es)
EP (2) EP2906681B1 (es)
JP (1) JP6329554B2 (es)
KR (1) KR20150068998A (es)
CN (2) CN104837984A (es)
AU (1) AU2013328615B2 (es)
BR (1) BR112015008052A2 (es)
CA (1) CA2887133C (es)
EA (1) EA201590488A1 (es)
ES (2) ES2905107T3 (es)
IL (1) IL238024A0 (es)
MX (1) MX365435B (es)
SG (2) SG11201502638YA (es)
TR (1) TR201904022T4 (es)
WO (1) WO2014057109A1 (es)
ZA (1) ZA201502433B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201503308XA (en) 2012-11-07 2015-05-28 Glycovaxyn Ag PRODUCTION OF RECOMBINANT VACCINE IN <i>E. COLI</i> BY ENZYMATIC CONJUGATION
NZ707777A (en) 2013-01-17 2019-12-20 X4 Pharmaceuticals Austria Gmbh Mdr e. coli specific antibody
US20160177355A1 (en) * 2013-03-14 2016-06-23 Adam C. Fisher Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
EP3055416B1 (en) 2013-10-11 2020-01-22 GlaxoSmithKline Biologicals S.A. Methods of host cell modification
EP3110441B1 (en) 2014-02-24 2024-04-03 GlaxoSmithKline Biologicals S.A. Novel polysaccharide and uses thereof
ES2805000T3 (es) * 2014-04-17 2021-02-10 Glaxosmithkline Biologicals Sa Células huéspedes modificadas y usos de las mismas
US11071289B2 (en) * 2014-08-14 2021-07-27 Biocytogen Boston Corp DNA knock-in system
JP6764872B2 (ja) 2015-02-26 2020-10-07 ヴァックスニューモ エルエルシーVaxnewmo Llc アシネトバクター(Acinetobacter)O−オリゴサッカリルトランスフェラーゼおよびその使用
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
CN106801029B (zh) * 2017-01-22 2020-05-01 山东大学 一株重组大肠杆菌及其在制备抗志贺氏菌的糖疫苗中的应用
CN109385417A (zh) * 2017-08-03 2019-02-26 华东理工大学 体内dna无缝组装方法
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
EP3806881B1 (en) 2018-06-16 2025-10-08 Vaxnewmo Llc Glycosylated comp pilin variants, methods of making and uses thereof
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20210088615A (ko) * 2018-10-31 2021-07-14 지머젠 인코포레이티드 Dna 라이브러리의 다중 결정적 어셈블리
AU2019404924B2 (en) 2018-12-21 2025-09-18 Vaxnewmo Llc O-linked glycosylation recognition motifs
JOP20210256A1 (ar) 2019-03-18 2023-01-30 Janssen Pharmaceuticals Inc متقارن حيوي لعديدات سكاريد المستضدات-o للإشريكية القولونية، طرائق إنتاجه، وطرائق استخدامه
KR102574882B1 (ko) 2019-03-18 2023-09-04 얀센 파마슈티칼즈, 인코포레이티드 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
HUE066794T2 (hu) 2019-08-09 2024-09-28 Glaxosmithkline Biologicals Sa Mutált PGLB oligoszachariltranszferáz enzimek
US20230346902A1 (en) * 2020-06-18 2023-11-02 Glaxosmithkline Biologicals Sa Shigella-Tetravalent (Shigella4V) Bioconjugate
CA3185639A1 (en) 2020-06-25 2021-12-30 Glaxosmithkline Biologicals Sa Vaccine
PH12023550020A1 (en) 2020-09-17 2024-03-11 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and uses thereof
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
JP2022099419A (ja) * 2020-12-23 2022-07-05 トヨタ自動車株式会社 形質転換用プラスミド及びこれを用いた形質転換体の製造方法、並びに形質転換方法
US20250270520A1 (en) 2021-02-11 2025-08-28 Glaxosmithkline Biologicals Sa Mutated pglb oligosaccharyltransferase enzymes
WO2022214620A1 (en) 2021-04-08 2022-10-13 Janssen Pharmaceuticals, Inc. Process for bioconjugate production
CN113528410A (zh) * 2021-06-23 2021-10-22 云舟生物科技(广州)有限公司 一种用于快速高效诱导表达外源蛋白的大肠杆菌工程菌及其制备方法与应用
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition
JP2024139548A (ja) * 2023-03-27 2024-10-09 株式会社豊田中央研究所 遺伝子発現方法
WO2025172892A1 (en) 2024-02-16 2025-08-21 Glaxosmithkline Biologicals Sa Modified proteins and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0750671A1 (en) * 1994-03-09 1997-01-02 Abbott Laboratories Transgenic animals producing oligosaccharides and glycoconjugates
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1364007A1 (en) * 2000-11-07 2003-11-26 Wilfried A. Jefferies Circular extra-chromosomal dna elements
US7126039B2 (en) * 2001-03-21 2006-10-24 Geron Corporation Animal tissue with carbohydrate antigens compatible for human transplantation
US7674621B2 (en) * 2004-05-21 2010-03-09 The United States Of America As Represented By The Department Of Health And Human Services Plasmids and phages for homologous recombination and methods of use
WO2006130925A1 (en) * 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
US8173657B2 (en) 2006-03-23 2012-05-08 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
EP3427749A1 (en) * 2008-02-20 2019-01-16 GlaxoSmithKline Biologicals SA Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
SG185433A1 (en) 2010-05-06 2012-12-28 Glycovaxyn Ag Capsular gram-positive bacteria bioconjugate vaccines

Also Published As

Publication number Publication date
SG11201502638YA (en) 2015-05-28
AU2013328615B2 (en) 2017-04-20
ES2905107T3 (es) 2022-04-07
KR20150068998A (ko) 2015-06-22
EA201590488A1 (ru) 2015-09-30
EP2906681A1 (en) 2015-08-19
TR201904022T4 (tr) 2019-04-22
CN104837984A (zh) 2015-08-12
EP3527663B1 (en) 2021-12-01
WO2014057109A1 (en) 2014-04-17
BR112015008052A2 (pt) 2017-11-28
US20150267207A1 (en) 2015-09-24
ES2720040T3 (es) 2019-07-17
AU2013328615A1 (en) 2015-04-30
US20190218561A1 (en) 2019-07-18
EP2906681B1 (en) 2019-01-09
CA2887133C (en) 2022-05-03
JP6329554B2 (ja) 2018-05-23
SG10201800777PA (en) 2018-02-27
EP3527663A1 (en) 2019-08-21
CN110423716A (zh) 2019-11-08
MX365435B (es) 2019-06-03
CA2887133A1 (en) 2014-04-17
IL238024A0 (en) 2015-05-31
JP2015533497A (ja) 2015-11-26
ZA201502433B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
MX2015004649A (es) Metodos de modificacion de celulas huesped.
MX371513B (es) Metodos de modificacion de celulas huespedes.
IN2014CN03468A (es)
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
MX2012011774A (es) Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que codifican los mismos.
EA024121B9 (ru) Композиции эндорибонуклеаз и способы их использования
IN2014CN00597A (es)
IN2014CN00650A (es)
MX352023B (es) Variantes de alfa-amilasa con estabilidad mejorada.
IN2014DN10996A (es)
MX355356B (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
PH12016500395A1 (en) Cell penetrating conjugates and methods of use thereof
MX351043B (es) Metodos para modificacion genomica.
MX2013007997A (es) Polipeptidos que tienen actividad de incremento celulolitico y polinucleotidos que codifican para los mismos.
MX2014004539A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
WO2013188638A3 (en) Endoribonucleases and methods of use thereof
NZ701099A (en) Ketol-acid reductoisomerase enzymes and methods of use
IN2014CN02469A (es)
GB2518764A8 (en) Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
MX2021013104A (es) Variantes de lipasa y polinucleotidos que las codifican.
MX2012004579A (es) Recombinacion homologa en genoma nuclear de algas.
MY180183A (en) Methods and compositions for preventing norleucine misincorporation into proteins
IN2014CN03187A (es)

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A.

FG Grant or registration